癌症基因组图谱(TCGA)数据库分析发现胶质母细胞瘤患者中白细胞介素-13受体α1和α2基因表达与不良预后及耐药呈负相关关系
该研究利用癌症基因组图谱(TCGA)公共数据库的基因表达(微阵列)和临床数据,分析胶质母细胞瘤(GBM)中IL-13受体α1和α2表达与严重程度及预后的关系。结果显示超过40%的GBM样本IL-13Rα2 mRNA高阳性(Log2 ≥ 2),而IL-13Rα1 mRNA高阳性样本不足16%;高表达IL-13Rα1和α2的肿瘤患者无论接受何种治疗,生存率均显著低于阴性肿瘤患者。IL-13Rα2基因表达与GBM对替莫唑胺(TMZ)化疗耐药相关。
要点
- 超过40%的GBM样本IL-13Rα2 mRNA高阳性(Log2 ≥ 2),不足16%的样本IL-13Rα1 mRNA高阳性。
- 高表达IL-13Rα1和α2的GBM患者无论接受何种治疗,生存率均显著低于阴性肿瘤患者。
- IL-13Rα2基因表达与GBM对替莫唑胺(TMZ)化疗耐药相关。
核心结论
- IL-13R mRNA高表达水平与患者不良预后直接相关,与IL-13Rα2相关的免疫抑制基因可能在肿瘤进展中发挥作用。
研究设计与样本
- 分析癌症基因组图谱(TCGA)公共数据库(现称为全球数据共享平台)中GBM的基因表达(微阵列)和临床数据。
- IL-13Rα2基因表达的微阵列数据通过RNA-Seq数据验证。
主要发现
- 超过40%的GBM样本IL-13Rα2 mRNA高阳性(Log2 ≥ 2),而IL-13Rα1 mRNA高阳性样本不足16%。
- 高表达IL-13Rα1和α2 mRNA的肿瘤患者无论接受何种治疗,生存率均显著低于IL-13Rα1和α2 mRNA阴性肿瘤患者。
- IL-13Rα2基因表达与GBM对替莫唑胺(TMZ)化疗耐药相关。
- IL-13Rα2基因表达似乎与IL-13R复合物其他链(IL-13Rα1或IL-4Rα)基因表达不相关,但IL-4Rα与IL-13Rα1基因表达呈正相关。
- 免疫抑制基因(如FMOD、CCL2、OSM等)在IL-13Rα2阳性肿瘤中高表达,而在IL-13Rα2阴性肿瘤中不表达。
关键数值与推荐
- IL-13Rα2 mRNA高阳性定义为Log2 ≥ 2。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. A variety of targeted agents are being tested in the clinic including cancer vaccines, immunotoxins, antibodies and T cell immunotherapy for GBM. We have previously reported that IL-13 receptor subunits α1 and α2 of IL-13R complex are overexpressed in GBM. We are investigating the significance of IL-13Rα1 and α2 expression in GBM tumors. In order to elucidate a possible relationship between IL-13Rα1 and α2 expression with severity and prognoses of subjects with GBM, we analyzed gene expression (by microarray) and clinical data available at the public The Cancer Genome Atlas (TCGA) database (Currently known as Global Data Commons). More than 40% of GBM samples were highly positive for IL-13Rα2 mRNA (Log2 ≥ 2) while only less than 16% samples were highly positive for IL-13Rα1 mRNA. Subjects with high IL-13Rα1 and α2 mRNA expressing tumors were associated with a significantly lower survival rate irrespective of their treatment compared to subjects with IL-13Rα1 and α2 mRNA negative tumors. We further observed that IL-13Rα2 gene expression is associated with GBM resistance to temozolomide (TMZ) chemotherapy. The expression of IL-13Rα2 gene did not seem to correlate with the expression of genes for other chains involved in the formation of IL-13R complex (IL-13Rα1 or IL-4Rα) in GBM. However, a positive correlation was observed between IL-4Rα and IL-13Rα1 gene expression. The microarray data of IL-13Rα2 gene expression was verified by RNA-Seq data. In depth analysis of TCGA data revealed that immunosuppressive genes (such as FMOD, CCL2, OSM, etc.) were highly expressed in IL-13Rα2 positive tumors, but not in IL-13Rα2 negative tumors. These results indicate a direct correlation between high level of IL-13R mRNA expression and poor patient prognosis and that immunosuppressive genes associated with IL-13Rα2 may play a role in tumor progression. These findings have important implications in understanding the role of IL-13R in the pathogenesis of GBM and potentially other cancers.
引用
- Han J, Puri RK. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme. J Neurooncol. 2017. PMID: 29168083. doi:10.1007/s11060-017-2680-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。